Clinical Trials · NCT02354781
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Jerry R. Mendell
- Enrollment
- 3
- Start date
- Jan 2015
- Locations
- 1 site, United States
- Primary endpoint
- Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32.